Specify a stock or a cryptocurrency in the search bar to get a summary
Paradigm Biopharmaceuticals Ltd
PARParadigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia. Address: 500 Collins Street, Melbourne, VIC, Australia, 3000
Analytics
WallStreet Target Price
0.7 AUDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PAR
Dividend Analytics PAR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PAR
Stock Valuation PAR
Financials PAR
Results | 2019 | Dynamics |